ABBOTT LABORATORIES acquires Alere Inc.
Snapshot
ABBOTT LABORATORIES acquired Alere Inc. for $51 per share, approximately $5.3 billion at close (originally announced at $56 per share / ~$5.8 billion equity value) in October 2017. The transaction was structured as all cash. Alere Inc. is a Waltham, Massachusetts, USA-based Diagnostics — point of care testing business.
- Acquirer
- ABBOTT LABORATORIES
- Target
- Alere Inc.
- Value
- $51 per share, approximately $5.3 billion at close (originally announced at $56 per share / ~$5.8 billion equity value)
- Date
- October 2017
- Type
- full acquisition
- Status
- ready
The deal at a glance
About this deal
ABBOTT LABORATORIES acquired Alere Inc. for $51 per share, approximately $5.3 billion at close (originally announced at $56 per share / ~$5.8 billion equity value), a transaction completed in October 2017, structured as all cash.
Alere Inc. operates in Diagnostics — point of care testing, is based in Waltham, Massachusetts, USA. Alere is a global leader in point-of-care diagnostics, providing rapid tests across infectious disease, cardiometabolic and toxicology testing close to the patient.
Once the transaction is completed, Abbott will become the leading diagnostics provider of point of care testing, with total diagnostics sales expected to exceed $7 billion after the close.
Leadership in the ~$5.5 billion point-of-care testing market, significantly expanding Abbott's global diagnostics presence. Integrated into Abbott's Diagnostics business
No advisory firms have been disclosed for this transaction.